| It's Official: Krypton Street Announces Galmed Pharmaceuticals (Nasdaq: GLMD) As Its Next Potential Breakout Idea For This Morning.
Here’s What We Can Tell You—So Far…
Just A Few Days Ago, On Friday 3/14/2025, Maxim Group Published A Report With A $12 Target On (GLMD) — Which Suggests An Upside Potential Of Over 597% From Its $1.72 Close.
There’s Less Than 1.65M Shares Listed In The Public Float For (GLMD) — Which Could Lead To The Potential For Significant Swings If Demand Begins To Shift.
According To Technical Indicators, (GLMD) Appears To Be Entering An Oversold Territory — Which Could Suggest The Potential For A Trend Reversal.
Take A Quick Look At Galmed Pharmaceuticals (NASDAQ: GLMD) While It’s Still Early—We Have All Eyes On This One Right Now.
March 17, 2025
Dear Reader,
Is Galmed Pharmaceuticals (Nasdaq: GLMD) on your screen yet?
(GLMD) reached $2.40 this morning, marking an approximate 39% move from Friday’s $1.72 close.
This showcased the potential for technical momentum as (GLMD) surpassed several key moving averages including: 5-Day: 1.7805 20-Day: 2.1752
With its 50-Day moving average at 2.5733, 100-Day at 2.8796, and 200-Day at 3.5727, we’re keeping a very close eye on (GLMD) right now.
If you’ve been following us for a while, you’ll know that the last time we highlighted (GLMD), it moved approximately 182% in under 24 hours.
Given that our last two Sunday Night Profiles showcased a combined 175% (approx.) in moves, we have every reason to believe that (GLMD) could be one to watch closely tomorrow morning.
You see, biotech and pharma are some of the most exciting industries, where a single breakthrough can turn an under-the-radar company into a major market player overnight.
Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on liver, metabolic, and fibro-inflammatory diseases.
The company is advancing Aramchol Meglumine, a potential treatment for Primary Sclerosing Cholangitis (PSC) and other fibrotic conditions.
Aramchol, in Phase 3 clinical development, has already demonstrated significant fibrosis improvement in patients with NASH and fibrosis, as published in Hepatology.
As the most advanced SCD-1 downregulator in clinical trials, Aramchol continues to show potential in multiple therapeutic areas. Learn more here.
On Friday, 3/14/2025, Maxim Group published a report which listed Galmed Pharmaceuticals (Nasdaq: GLMD) with a $12 target, which suggests an upside potential of over 597% from its $1.72 close.
Here’s 3 Reasons Why Galmed Pharmaceuticals (Nasdaq: GLMD) Is Topping Our Watchlist This Morning…
1. Analyst Coverage: Just a few days, on Friday 3/14/2025, Maxim Group published a report with a $12 target on (GLMD), which suggests an upside potential of over 597% from its $1.72 close.
2. Ultra Low Float: There’s less than 1.65M shares listed in the public float for (GLMD). This limited float could lead to the potential for significant swings if demand begins to shift.
3. Technical Indicators: According to technical indicators found on Barchart, (GLMD) appears to be entering an oversold territory, which could suggest the potential for a trend reversal.
Consider Adding Galmed Pharmaceuticals (Nasdaq: GLMD) to Your Radar Today…
When a profile like this starts catching momentum, things can move fast—we’ve seen it happen before.
Consider taking a look at (GLMD) while it’s still early.
(GLMD) is at the top of our screens right now.
Remember— the last time we covered (GLMD), it moved approximately 182% in less than 24 hours. Keep a lookout for my next update—it could be out very shortly. | 
No comments:
Post a Comment